Vertex Pharmaceuticals Incorpor (VRTX) Stock Analysis
Temp Headwind edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $428.38, but acceptable to hold if already in. Reasons: Concentration risk — Product: CF medicines; Earnings in 4 days (event risk).
Vertex is a global biotech with approved medicines for cystic fibrosis (CF), sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. Net revenues are substantially all derived from CF medicines, with a pipeline targeting IgA nephropathy, APOL1 kidney... Read more
Hold if already holding. Not a fresh buy at $428.38, but acceptable to hold if already in. Reasons: Concentration risk — Product: CF medicines; Earnings in 4 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 5.6/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 4d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCF medicines10-K Item 1A: 'Substantially all our net product revenues have been derived from the sale of our CF medicines'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $428.38, but acceptable to hold if already in. Reasons: Concentration risk — Product: CF medicines; Earnings in 4 days (event risk). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $493.55 (+15.2%), stop $409.77 (−4.5%), A.R:R 3.1:1. Score 5.6/10, moderate confidence.
Take-profit target: $493.55 (+15.5% upside). Target $493.55 (+15.2%), stop $409.77 (−4.5%), A.R:R 3.1:1. Stop-loss: $409.77.
Concentration risk — Product: CF medicines; Earnings in 4 days (event risk); Negative momentum.
Vertex Pharmaceuticals Incorpor trades at a P/E of 27.6 (forward 19.4). TrendMatrix value score: 4.9/10. Verdict: Hold.
40 analysts cover VRTX with a consensus score of 4.1/5. Average price target: $548.
What does Vertex Pharmaceuticals Incorpor do?Vertex is a global biotech with approved medicines for cystic fibrosis (CF), sickle cell disease, transfusion-dependent...
Vertex is a global biotech with approved medicines for cystic fibrosis (CF), sickle cell disease, transfusion-dependent beta thalassemia, and acute pain. Net revenues are substantially all derived from CF medicines, with a pipeline targeting IgA nephropathy, APOL1 kidney disease, type 1 diabetes, and neuropathic pain.